Guo M, Yao Z, Jiang C, Songyang Z, Gan L, Xiong Y
Front Immunol. 2023; 14:1161522.
PMID: 37063858
PMC: 10102373.
DOI: 10.3389/fimmu.2023.1161522.
Harris P, Hansen R, Gray M, Massoud O, McGuire B, Shoreibah M
World J Gastroenterol. 2019; 25(13):1550-1559.
PMID: 30983815
PMC: 6452232.
DOI: 10.3748/wjg.v25.i13.1550.
Chen C, Lee M, Liu J, Yang H
Hepat Oncol. 2018; 2(1):1-4.
PMID: 30190979
PMC: 6095179.
DOI: 10.2217/hep.14.32.
Yu Q, Qian W, Wang J, Wu Y, Zhang J, Chen W
Oncol Lett. 2018; 15(5):8088-8094.
PMID: 29731916
PMC: 5921256.
DOI: 10.3892/ol.2018.8347.
Xia H, Wen J, Zhao W, Gu D, Hu Z, Chen J
Oncotarget. 2017; 8(41):69823-69832.
PMID: 29050244
PMC: 5642519.
DOI: 10.18632/oncotarget.19310.
coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease.
Oussalah A, Avogbe P, Guyot E, Chery C, Gueant-Rodriguez R, Ganne-Carrie N
Oncotarget. 2017; 8(38):62842-62857.
PMID: 28968953
PMC: 5609885.
DOI: 10.18632/oncotarget.11327.
HBV suppresses thapsigargin-induced apoptosis via inhibiting CHOP expression in hepatocellular carcinoma cells.
Zhao D, Liu Y, Liu X, Li T, Xin Z, Zhu X
Oncol Lett. 2017; 14(4):4403-4409.
PMID: 28943956
PMC: 5604123.
DOI: 10.3892/ol.2017.6666.
Association of VEGFA polymorphisms with susceptibility and clinical outcome of hepatocellular carcinoma in a Chinese Han population.
Liu F, Luo L, Wei Y, Wang W, Wen T, Yang J
Oncotarget. 2017; 8(10):16488-16497.
PMID: 28147320
PMC: 5369979.
DOI: 10.18632/oncotarget.14870.
The contribution of serum hepatitis B virus load in the carcinogenesis and prognosis of hepatocellular carcinoma: evidence from two meta-analyses.
Chen X, Wu F, Liu Y, Lou J, Zhu B, Zou L
Oncotarget. 2016; 7(31):49299-49309.
PMID: 27384478
PMC: 5226509.
DOI: 10.18632/oncotarget.10335.
Nine susceptibility loci for hepatitis B virus-related hepatocellular carcinoma identified by a pilot two-stage genome-wide association study.
Qu L, Jin F, Guo Y, Liu T, Xue R, Huang X
Oncol Lett. 2016; 11(1):624-632.
PMID: 26870257
PMC: 4727098.
DOI: 10.3892/ol.2015.3958.
Genetic variations in STAT4,C2,HLA-DRB1 and HLA-DQ associated with risk of hepatitis B virus-related liver cirrhosis.
Jiang D, Ma X, Wu X, Peng L, Yin J, Dan Y
Sci Rep. 2015; 5:16278.
PMID: 26538132
PMC: 4633722.
DOI: 10.1038/srep16278.
Genetic polymorphisms in antioxidant enzyme genes and susceptibility to hepatocellular carcinoma in Chinese population: a case-control study.
Su S, He K, Li J, Wu J, Zhang M, Feng C
Tumour Biol. 2015; 36(6):4627-32.
PMID: 25894370
DOI: 10.1007/s13277-015-3110-2.
Polymorphisms in microRNA target sites of forkhead box O genes are associated with hepatocellular carcinoma.
Tan C, Liu S, Tan S, Zeng X, Yu H, Li A
PLoS One. 2015; 10(3):e0119210.
PMID: 25739100
PMC: 4357486.
DOI: 10.1371/journal.pone.0119210.
Epigenetically silenced long noncoding-SRHC promotes proliferation of hepatocellular carcinoma.
Zheng H, Yang S, Yang Y, Yuan S, Wu F, Wang L
J Cancer Res Clin Oncol. 2014; 141(7):1195-203.
PMID: 25512078
DOI: 10.1007/s00432-014-1871-4.
Variants identified by hepatocellular carcinoma and chronic hepatitis B virus infection susceptibility GWAS associated with survival in HBV-related hepatocellular carcinoma.
Li C, Bi X, Huang Y, Zhao J, Li Z, Zhou J
PLoS One. 2014; 9(7):e101586.
PMID: 24987808
PMC: 4079718.
DOI: 10.1371/journal.pone.0101586.
Promoter polymorphisms of DNA methyltransferase 3B and risk of hepatocellular carcinoma.
Lao Y, Wu H, Zhao C, Wu Q, Qiao F, Fan H
Biomed Rep. 2014; 1(5):771-775.
PMID: 24649027
PMC: 3917017.
DOI: 10.3892/br.2013.142.
Cyclin D1 G870A polymorphism and the risk of hepatocellular carcinoma in a Chinese population.
Hu Z, Zhou Z, Xiong G, Wang Y, Lai Y, Deng L
Tumour Biol. 2014; 35(6):5607-12.
PMID: 24570185
DOI: 10.1007/s13277-014-1741-3.
New insights on non-B non-C hepatocellular carcinoma in mid Delta Region, Egypt.
Abou El Azm A, Yousef M, Mansour N, Awad A, El Dardiry S, Abdel Aziz I
J Gastrointest Cancer. 2014; 45(3):276-83.
PMID: 24488435
DOI: 10.1007/s12029-013-9573-8.
Association between an insertion/deletion polymorphism within 3'UTR of SGSM3 and risk of hepatocellular carcinoma.
Wang C, Zhao H, Zhao X, Wan J, Wang D, Bi W
Tumour Biol. 2013; 35(1):295-301.
PMID: 23918301
DOI: 10.1007/s13277-013-1039-x.
Insertion/deletion polymorphisms in the promoter region of BRM contribute to risk of hepatocellular carcinoma in Chinese populations.
Gao X, Huang M, Liu L, He Y, Yu Q, Zhao H
PLoS One. 2013; 8(1):e55169.
PMID: 23359823
PMC: 3554679.
DOI: 10.1371/journal.pone.0055169.
